Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics granted inducement options to purchase an aggregate of 92,200 shares of common stock to four new employees pursuant to its 2023 Employment Inducement Award Plan. The awards were approved by the Compensation Committee as a material inducement to employment and vest over four years, with 25% vesting on the first anniversary and the remainder in equal annual installments.
Key figures
- Shares Offered
- 92200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.